<p>Merit Medical Systems, Inc.（纳斯达克代码：MMSI - 获取免费报告）在周一创下了 52 周的新低，此前 Canaccord Genuity Group 将该股票的目标价从 90.00 美元下调至 85.00 美元。Canaccord Genuity Group 目前对该股票维持买入评级。Merit Medical Systems 的交易最低价为 61.31 美元，最后交易价为 61.89 美元，成交量为 2526188 股。该股票此前收盘价为 62.01 美元。</p>
<p>其他几位股票研究分析师最近也对该公司发布了报告。BTIG Research 在 2 月 6 日（星期五）发布的报告中开始覆盖 Merit Medical Systems。他们对该股票设定了 “买入” 评级和 107.00 美元的目标价。花旗集团在 4 月 20 日（星期一）的研究报告中重申了对 Merit Medical Systems 股票的 “跑赢大盘” 评级。罗伯特·W·贝尔德在周五的研究报告中对 Merit Medical Systems 股票设定了 83.00 美元的目标价。摩根大通将 Merit Medical Systems 股票的目标价从 95.00 美元下调至 77.00 美元，并在周五的报告中对该股票设定了 “增持” 评级。最后，巴林顿研究在 4 月 20 日（星期一）的研究报告中将 Merit Medical Systems 股票的目标价从 109.00 美元下调至 107.00 美元，并对该股票设定了 “跑赢大盘” 评级。八位研究分析师对该股票给予了买入评级，三位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，Merit Medical Systems 目前的平均评级为 “适度买入”，共识目标价为 92.80 美元。</p>
<p>获取 <strong>Merit Medical Systems</strong> 的提醒：</p>
<p><strong>获取我们对 Merit Medical Systems 的最新分析</strong></p>
<h2>机构投资者对 Merit Medical Systems 的看法</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。洛杉矶资本管理公司在第四季度收购了 Merit Medical Systems 的新头寸，价值 25000 美元。Maseco LLP 在第四季度收购了 Merit Medical Systems 的股份，价值 26000 美元。Salomon &amp; Ludwin LLC 在第三季度购买了 Merit Medical Systems 的新头寸，价值约 37000 美元。Torren Management LLC 在第四季度购买了 Merit Medical Systems 的新头寸，价值约 38000 美元。最后，Covestor Ltd 在第四季度将其在 Merit Medical Systems 的持股增加了 252.6%。Covestor Ltd 现在拥有 469 股该医疗器械供应商的股票，价值 41000 美元，此前在此期间又购买了 336 股。99.66% 的股票由机构投资者和对冲基金持有。</p>
<h2>Merit Medical Systems 股价下跌 8.9%</h2>
<p>该公司的市值为 37 亿美元，市盈率为 27.04，市盈增长比率为 1.75，贝塔值为 0.58。该公司的 50 日移动平均线为 70.68 美元，200 日移动平均线为 79.78 美元。公司的流动比率为 5.08，速动比率为 3.46，债务与股本比率为 0.45。</p>
<p>Merit Medical Systems（纳斯达克代码：MMSI - 获取免费报告）在 4 月 30 日（星期四）最后发布了其财报。这家医疗器械供应商报告本季度每股收益为 0.94 美元，超出分析师共识预期的 0.84 美元，超出 0.10 美元。该公司本季度的收入为 3.8188 亿美元，而共识预期为 3.7759 亿美元。Merit Medical Systems 的股本回报率为 13.54%，净利润率为 9.03%。与去年同期相比，Merit Medical Systems 的季度收入增长了 7.4%。在去年同期，该公司每股收益为 0.86 美元。Merit Medical Systems 已将其 2026 财年的指导目标设定为每股收益 4.010-4.150 美元。作为一个整体，分析师预计 Merit Medical Systems, Inc.在当前财年将发布每股收益 3.61 美元。</p>
<h2>Merit Medical Systems 公司简介</h2>
<p>（获取免费报告）</p>
<p>Merit Medical Systems, Inc.是一家全球制造和销售广泛医疗设备的公司，这些设备用于诊断和介入程序。公司的产品组合涵盖血管通路、引流、栓塞治疗和介入肿瘤学设备，以及射频消融系统和止血解决方案。这些产品为重症监护环境中的医生和医院提供服务，并支持多个专业领域的微创治疗选择，包括心脏病学、放射学、肿瘤学、神经学和内窥镜检查。</p>
<p>Merit Medical Systems 成立于 1987 年，由 Fred Lampropoulos 创办，通过有机发展和有针对性的收购不断壮大，以扩展其技术产品和地理覆盖范围。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，优于 Merit Medical Systems</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Merit Medical Systems 吗？</h2>
<p>在你考虑投资 Merit Medical Systems 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Merit Medical Systems 并不在名单上。</p>
<p>虽然 Merit Medical Systems 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Merit医疗系统

<p>Merit 医疗系统（NASDAQ:MMSI）在 Canaccord Genuity 将其目标价从 90 美元下调至 85 美元后，达到了 61.31 美元的新 12 个月低点，维持买入评级。该股票交易价格为 61.89 美元，成交量为 2,526,188 股。分析师的评级各不相同，八位推荐买入，三位维持持有。该公司报告第一季度每股收益为 0.94 美元，超出预期，收入为 3.8188 亿美元，同比增长 7.4%。Merit 医疗系统的市值为 37 亿美元，市场共识目标价为 92.80 美元</p>

<p>Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) reached a new 52-week low on Monday after Canaccord Genuity Group lowered their price target on the stock from $90.00 to $85.00. Canaccord Genuity Group currently has a buy rating on the stock. Merit Medical Systems traded as low as $61.31 and last traded at $61.89, with a volume of 2526188 shares. The stock had previously closed at $62.01.</p>
<div class="lb-trans"><p>Merit Medical Systems, Inc.（纳斯达克代码：MMSI - 获取免费报告）在周一创下了 52 周的新低，此前 Canaccord Genuity Group 将该股票的目标价从 90.00 美元下调至 85.00 美元。Canaccord Genuity Group 目前对该股票维持买入评级。Merit Medical Systems 的交易最低价为 61.31 美元，最后交易价为 61.89 美元，成交量为 2526188 股。该股票此前收盘价为 62.01 美元。</p>
</div><p>Several other equities research analysts also recently issued reports on the company. BTIG Research initiated coverage on Merit Medical Systems in a report on Friday, February 6th. They set a &#34;buy&#34; rating and a $107.00 price objective on the stock. Citigroup reiterated an &#34;outperform&#34; rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Robert W. Baird set a $83.00 price target on shares of Merit Medical Systems in a research report on Friday. JPMorgan Chase &amp; Co. cut their price target on shares of Merit Medical Systems from $95.00 to $77.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday. Finally, Barrington Research reduced their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an &#34;outperform&#34; rating on the stock in a research note on Monday, April 20th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Merit Medical Systems presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $92.80.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对该公司发布了报告。BTIG Research 在 2 月 6 日（星期五）发布的报告中开始覆盖 Merit Medical Systems。他们对该股票设定了 “买入” 评级和 107.00 美元的目标价。花旗集团在 4 月 20 日（星期一）的研究报告中重申了对 Merit Medical Systems 股票的 “跑赢大盘” 评级。罗伯特·W·贝尔德在周五的研究报告中对 Merit Medical Systems 股票设定了 83.00 美元的目标价。摩根大通将 Merit Medical Systems 股票的目标价从 95.00 美元下调至 77.00 美元，并在周五的报告中对该股票设定了 “增持” 评级。最后，巴林顿研究在 4 月 20 日（星期一）的研究报告中将 Merit Medical Systems 股票的目标价从 109.00 美元下调至 107.00 美元，并对该股票设定了 “跑赢大盘” 评级。八位研究分析师对该股票给予了买入评级，三位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，Merit Medical Systems 目前的平均评级为 “适度买入”，共识目标价为 92.80 美元。</p>
</div><p>Get <strong>Merit Medical Systems</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Merit Medical Systems</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Analysis on Merit Medical Systems</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Merit Medical Systems 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Merit Medical Systems</h2>
<div class="lb-trans"><h2>机构投资者对 Merit Medical Systems 的看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in Merit Medical Systems in the fourth quarter worth $25,000. Maseco LLP acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth $26,000. Salomon &amp; Ludwin LLC bought a new position in shares of Merit Medical Systems in the 3rd quarter worth about $37,000. Torren Management LLC bought a new position in shares of Merit Medical Systems in the 4th quarter worth about $38,000. Finally, Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 336 shares during the period. 99.66% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。洛杉矶资本管理公司在第四季度收购了 Merit Medical Systems 的新头寸，价值 25000 美元。Maseco LLP 在第四季度收购了 Merit Medical Systems 的股份，价值 26000 美元。Salomon &amp; Ludwin LLC 在第三季度购买了 Merit Medical Systems 的新头寸，价值约 37000 美元。Torren Management LLC 在第四季度购买了 Merit Medical Systems 的新头寸，价值约 38000 美元。最后，Covestor Ltd 在第四季度将其在 Merit Medical Systems 的持股增加了 252.6%。Covestor Ltd 现在拥有 469 股该医疗器械供应商的股票，价值 41000 美元，此前在此期间又购买了 336 股。99.66% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Merit Medical Systems Trading Down 8.9%</h2>
<div class="lb-trans"><h2>Merit Medical Systems 股价下跌 8.9%</h2>
</div><p>The firm has a market cap of $3.70 billion, a P/E ratio of 27.04, a P/E/G ratio of 1.75 and a beta of 0.58. The business's 50-day moving average is $70.68 and its two-hundred day moving average is $79.78. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>该公司的市值为 37 亿美元，市盈率为 27.04，市盈增长比率为 1.75，贝塔值为 0.58。该公司的 50 日移动平均线为 70.68 美元，200 日移动平均线为 79.78 美元。公司的流动比率为 5.08，速动比率为 3.46，债务与股本比率为 0.45。</p>
</div><p>Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.10. The company had revenue of $381.88 million during the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.Merit Medical Systems's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, analysts expect that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Merit Medical Systems（纳斯达克代码：MMSI - 获取免费报告）在 4 月 30 日（星期四）最后发布了其财报。这家医疗器械供应商报告本季度每股收益为 0.94 美元，超出分析师共识预期的 0.84 美元，超出 0.10 美元。该公司本季度的收入为 3.8188 亿美元，而共识预期为 3.7759 亿美元。Merit Medical Systems 的股本回报率为 13.54%，净利润率为 9.03%。与去年同期相比，Merit Medical Systems 的季度收入增长了 7.4%。在去年同期，该公司每股收益为 0.86 美元。Merit Medical Systems 已将其 2026 财年的指导目标设定为每股收益 4.010-4.150 美元。作为一个整体，分析师预计 Merit Medical Systems, Inc.在当前财年将发布每股收益 3.61 美元。</p>
</div><h2>Merit Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>Merit Medical Systems 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.</p>
<div class="lb-trans"><p>Merit Medical Systems, Inc.是一家全球制造和销售广泛医疗设备的公司，这些设备用于诊断和介入程序。公司的产品组合涵盖血管通路、引流、栓塞治疗和介入肿瘤学设备，以及射频消融系统和止血解决方案。这些产品为重症监护环境中的医生和医院提供服务，并支持多个专业领域的微创治疗选择，包括心脏病学、放射学、肿瘤学、神经学和内窥镜检查。</p>
</div><p>Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.</p>
<div class="lb-trans"><p>Merit Medical Systems 成立于 1987 年，由 Fred Lampropoulos 创办，通过有机发展和有针对性的收购不断壮大，以扩展其技术产品和地理覆盖范围。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Merit Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于 Merit Medical Systems</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merit Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Merit Medical Systems 吗？</h2>
</div><p>Before you consider Merit Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Merit Medical Systems 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Merit Medical Systems 并不在名单上。</p>
</div><p>While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merit Medical Systems 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Merit Medical Systems (NASDAQ:MMSI) Reaches New 12-Month Low Following Analyst Downgrade

Market Beat

花旗

摩根大通

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Merit 医疗系统（NASDAQ:MMSI）在分析师下调评级后创下新的 12 个月低点